Almalag Haya M, Alosaimi Nora, Alqahtani Reem, Alharbi Rahaf, Alarfaj Abdulrahman S, Omair Mohammed A, Bedaiwi Mohamed, Qurtas Iman, Almaghlouth Ibrahim, Alsabhan Jawza F, Alsuwayni Bashayr, Juffali Lobna Al
Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Rheumatology Unit, Department of Medicine, King Saud University, Riyadh 11451, Saudi Arabia.
Healthcare (Basel). 2025 Jan 2;13(1):71. doi: 10.3390/healthcare13010071.
This study aimed to assess patient activation using patient activation measure 13 (PAM-13) in systemic lupus erythematosus (SLE), psoriatic arthritis (PsA), and axial spondyloarthritis (axSPA). A cross-sectional study was conducted involving patients with three rheumatological conditions (SLE, PsA, and axSPA). Patients were contacted either at the clinic or through social media platforms. Data, including demographics, PAM 13, Arabic compliance questionnaire for rheumatology (ACQR), and disease-related activity scores, were collected electronically. The analyses included Chi-squared tests, linear regression, and binary logistic regression. Overall, 418 patients were recruited (SLE = 323, PsA = 65, and axSPA = 30), with a mean (±SD) age of 42 ± 11 years and a female predominance (88%). PAM-13 scores did not significantly differ between the rheumatological disorders. Patients with axSPA showed significantly higher compliance than those with SLE or PsA ( = 0.012). In regression models, patients with PsA were more likely to be in activation level 1, with an OR of 2.890 (95% CI: 1.044-8.000, = 0.0041), whereas patients with axSPA were more likely to be in activation level 4, with an OR of 2.460 (95% CI: 1.122-5.393, = 0.025). The SLEDAI score was inversely related to the PAM-13 score (Pearson's correlation coefficient = -0.221, < 0.001). This study explored the levels of activation and medication compliance in different rheumatological conditions. Larger studies are needed to confirm these findings and explore the challenges and opportunities for improving compliance and activation.
本研究旨在使用患者激活度量表13（PAM - 13）评估系统性红斑狼疮（SLE）、银屑病关节炎（PsA）和中轴型脊柱关节炎（axSPA）患者的激活情况。开展了一项横断面研究，纳入患有三种风湿性疾病（SLE、PsA和axSPA）的患者。通过诊所或社交媒体平台联系患者。以电子方式收集包括人口统计学数据、PAM 13、阿拉伯语风湿病依从性问卷（ACQR）以及疾病相关活动评分等数据。分析包括卡方检验、线性回归和二元逻辑回归。总体而言，招募了418名患者（SLE = 323例，PsA = 65例以及axSPA = 30例），平均（±标准差）年龄为42±11岁，女性占多数（88%）。PAM - 13评分在这些风湿性疾病之间无显著差异。axSPA患者显示出比SLE或PsA患者显著更高的依从性（P = 0.012）。在回归模型中，PsA患者更有可能处于激活水平1，比值比为2.890（95%置信区间：1.044 - 8.000，P = 0.0041），而axSPA患者更有可能处于激活水平4，比值比为2.460（95%置信区间：1.122 - 5.393，P = 0.025）。SLE疾病活动指数（SLEDAI）评分与PAM - 13评分呈负相关（皮尔逊相关系数 = -0.221，P < 0.001）。本研究探讨了不同风湿性疾病中的激活水平和药物依从性。需要开展更大规模的研究来证实这些发现，并探索改善依从性和激活情况的挑战与机遇。
